In vitro studies were undertaken to determine whether the level of anti-DNA antibody can be modulated in humans with systemic lupus erythematosus (SLE). DNA fragments of different sizes, i.e., oligonucleotide (N2030) or oligonucleotide (No-100), were covalently linked either to human gammaglobulin (HGG) and used as tolerogens or to keyhole limpet hemocyanin and used as immunogens. Experiments were done to determine whether such tolerogens specifically diminish antibodies to denatured DNA, native DNA, or both. PBL were obtained from 87 patients with SLE, 55 of whom spontaneously produced anti-DNA antibodies in vitro. Furthermore, of these 55 test subjects 23 made anti-DNA antibodies in response to antigen challenge in vitro. Exposure of PBL to tolerogenic oligonucleotide-HGG reduced spontaneous antibody formation in 34 of the 55 patients' PBL and abrogated the in vitro-induced response in all instances. The suppression was tolerogen specific. In some SLE patients lymphoid cells were suppressed by both (N-10,,,)-HGG and (N20 30)-HGG, while in others lymphoid cells were suppressed by only one. Longitudinal studies of spontaneous antibody production showed that the same tolerogens consistently reduced anti-DNA antibody formation in lymphoid cells of 12 patients on several occasions over a 2-yr interval, but in 8 others the results were either variable or inconsistent. In contrast, tolerogens consistently abrogated the antigen-induced response in all 23 patients' PBL. These results obtained in humans in vitro suggest that the principle of carrier-determined tolerance could be applied as a specific therapy for SLE in vivo.
Introduction
Systemic lupus erythematosus (SLE) is the autoimmune disease par excellence because many autoantibodies to self-antigens, including nucleic acid, are formed (1) (2) (3) . Whether DNA is an antigenic stimulus in SLE has been a subject of controversy (4, 5) , not only because some anti-DNA antibodies cross-react with antigens irrelevant to DNA, but also because other antigens such as cardiolipin and Klebsiella may give rise to antibodies cross-reacting with DNA (6) (7) (8) (9) (10) (11) (12) (13) . Likewise, the presence of anti-DNA antibodies may or may not correlate with disease activity (14) (15) (16) (17) . Despite these paradoxes, antinucleic acid antibodies in general, and anti-native DNA (n-DNA)' in particular, are still the hallmark of SLE (18, 19) . Moreover, antibodies to DNA have been clearly shown to play a role in the mechanism of tissue injury both in murine and human SLE (20, 21) . Consequently, specific suppression of anti-DNA antibody by the induction of immunologic tolerance to DNA may have therapeutic value. One way to test this idea is to determine whether conjugates of DNA fragments (oligonucleotides) covalently linked to the self-carrier human gammaglobulin (HGG) specifically modulate anti-DNA antibodies in vitro. The data suggest that both spontaneous and antigen-induced anti-DNA antibodies produced by cultured lymphoid cells from SLE patients can be specifically diminished by oligonucleotides covalently bound to HGG.
Methods
Preparation of antigens and tolerogens. Calf thymus DNA was purchased from Worthington Biochemical Corp. (Freehold, NJ). It was further purified to remove RNA and protein, and then digested with DNase as previously described (22) . Total DNA digest was fractionated by chromatography on Ultragel (Pharmacia Fine Chemicals, Piscataway, NJ) as seen in Fig. 1 , and fractions were collected. Two sizes of DNA fragments containing either 10-100 (Nslo1) or 20-30 (N20 30) bp were obtained. The size ofthe fragments was determined by PAGE. These oligonucleotide fragments were linked to a protein carrier using glutaraldehyde as a linking agent in a two-step procedure as previously described (23) . Two types of immunogens were prepared: total DNA digest (NIo-100) and oligonucleotides (N20 30) linked to keyhole limpet hemocyanin (KLH). Likewise, two types of tolerogens were prepared:
(NIo-loo) and (N20 30) linked to HGG as previously described (22) . HGG suitable for intravenous therapy was obtained either from Immuno AG or Sandoz Ltd. (Basel, Switzerland) (Sandoglobulin). For specificity controls, we used similar DNA fragments and HGG that were not covalently bound together. In addition, in some instances we used tetranucleoside linked to HGG, prepared as previously described (24) , or the immunogen (oligonucleotide) linked to KLH.
Patient population. 87 people with SLE were studied. 79 were patients of Dr. A. Steinberg at the Arthritis Branch of the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (Bethesda, MD) and 8 were from the Children's Hospital in Boston. All SLE patients satisfied the diagnostic criteria of the American Rheumatism Association (25). Clinical activity was assessed by the physicians on the basis of signs and symptoms (rash, serositis, arthritis, central nervous system disease, and renal disease) at the time of blood drawing. No For specificity controls we used either nucleoside oligonucleotides linked to KLH. We found that a with tolerogens was sufficient to decrease spontai mation and that a 2-4-d incubation gave similar n 18-h incubation was chosen, after which the cells times and resuspended in fresh medium for 4 d. E bation, antigen was either added as described al depending on whether eitherspontaneous or ar body formation was being measured. The cellswer times and resuspended in fresh medium for 6 d. ( and antibody was assayed in the culture supernatU Solid-phase RIA. Polyvinylchloride microtit Laboratories, Inc., Arlington, VA) were coatedw sulfate in distilled water for 90 min, rinsed thorc water, then coated witheither 50 Mg/ml n-DNA or tured DNA (d-DNA). Ovalbumin was used at the as an irrelevant target antigen. All antigens were 40C overnight for maximal coating. The coated plates were rinsed three times with a washing solution of 0.25% fetal bovine serum and 0.05% Tween 20 in PBS, pH 7.4.
A blocking solution of 1% BSA and 3% fetal bovine serum in PBS was then added to all wells for 1 h at room temperature. The plate was again washed three times with washing solution, then samples of the culture supernatants were added and allowed to incubate at 370C for 90 min. Again the plate was washed three times before being developed with 251-(Fab')2 adjusted to 106 cpm/ml (100 sl/well) in the blocking solution above. (Fab')2 was obtained by pepsin digestion of rabbit anti-human Ig which recognizes both IgG and IgM. In some instances, to detect class-specific antibody, '25I-(Fab)2 goat anti-human reactive with IgM or IgG (New England Nuclear Boston, MA) were used. Plates were developed for 90 min at room temperature, washed as above with washing buffer, and then dried. The plates were cut with scissors and each well was counted for bound radioactivity in a gamma counter.
[A digest to obtain Antibodies to n-DNA, d-DNA, or ovalbumin secreted into the culture 43-120 represent supernatant were assayed in triplicate. Background values determined epresent oligonu-either by the antigen with CM or the irrelevant antigen ovalbumin Ode (both used as were <600±30 cpm, and were subtracted from the experimental values. The data expressed as cpm/culture are the net geometric means of three separate cultures above background. A two-tailed t test was used to analyze the significance of the data. For spontaneous antibody )r signs were categoproduction after preincubation with tolerogen, a 30% reduction (> 2 ive. 90% of patients SD compared with controls) was chosen as significant. bumin. The range of the spontaneous response expressed as in/stfretptomesycin, net cpm/culture 2 SD above background) varied as follows:
ation is referred to 1-150, 8%; 150-300, 22%; 300-1,000, 22%; 1,000-3,000, e and maintained at itigen-induced anti-Specific reduction of spontaneous anti-DNA antibody fore again washed three mation byaligonucleotide-HGG tolerogen. Initially, we deter-Cells were harvested mined the dose of tolerogen necessary to influence spontaneant.
ous anti-DNA antibody formation. Fig. 2 gesting that the observed reduction was not due to passive absorption of preformed antibody by tolerogen.
Since two different sizes of DNA fragments were used to construct tolerogens (either [Nls1lo]-HGG or [N20-30]-HGG), we determined whether either one or both conjugates could diminish anti-DNA spontaneously formed in vitro. The results are summarized in Table II . Antibody was reduced by one or both types of tolerogen in 34 of 55 patients' PBL (60%) that produced anti-DNA spontaneously. The specificity of the reduction of antibody spontaneously produced was examined in a number ofexperiments. A typical example is shown in Fig. 3 . DNA fragments must be covalently linked to the carrier (HGG) for the conjugate to be tolerogenic. In contrast, nucleoside linked to HGG failed to affect the response to d-DNA.
The specificity was further studied in a number of instances in which one type of tolerogen (either [NIo100]-HGG or [N20>0]-HGG) diminished the spontaneous response. This was done either by linking the same DNA fragment to an immunogenic carrier protein KLH or by using a DNA fragment ofa different size linked to HGG. One example of each is given in Fig. 4 . Depending on the type of immune response produced, the formation of antibody to either d-DNA, n-DNA, or both can be affected by tolerogen as seen in Fig. 4 . Exp. 1 shows a representative experiment in which the production of anti-d-DNA was diminished by both types of tolerogens, whereas Exp. 2 shows anti-n-DNA reduced by oligonucleotide (N2030)-HGG. Since some SLE patients' PBL spontaneously produced IgG class antibody to either d-DNA or n-DNA, we examined whether we could diminish this class of antibody.
Exp. 3 shows a representative experiment in which (NIO.100)-HGG suppressed IgG to both anti-d-DNA and anti-n-DNA. It should be emphasized (as seen in Table II ) that either one or both oligonucleotides' gammaglobulin conjugates failed to be tolerogenic in -40% of the cases. The reason could be either that T and/or B cells of this particular patient's PBL were resistant to tolerance induction, or that specificity of the antinucleic acid antibody produced did not correspond to the size ofthe DNA fragment used to construct a tolerogen. Therefore, it was critical to test the same tolerogenic conjugate on several occasions for the same patient's PBL. Longitudinal studyfor the diminution ofspontaneous antibody formation. There is considerable variability in the pro- duction of spontaneous antibody by PBL not only among patients but also within each patient. During a 2-yr interval we had the opportunity to study 20 patients' PBL. The results are summarized in Table III . They fall into two broad categories: in a population of 12 patients' PBL we found that the suppression ofanti-DNA antibody formation was both consistent and specific for the type of tolerogens used; on the other hand, in a population of eight SLE patients' PBL there is variability both in the ability oftolerogens to diminish antibody formation and in the formation and specificity of antibody produced.
Suppression ofantigen-induced antibody production. Next we determined whether pretreatment with tolerogen would influence the immune response after antigen challenge in vitro. This was done not only because production of spontaneous antibody to DNA is both small and variable, but also to determine whether the tolerogen could influence a booster response elicited by exogenous antigen challenge in vitro. We tested PBL from all 23 patients responding to antigen challenge in vitro. Six patients' PBL were tested more than once. Regardless of the type of tolerogen or immunogen used, we found that the antigen-induced response was abrogated by preincubation with tolerogen in all instances except one. This case was tolerized and immunized by both types of tolerogens and immunogens. One tolerogen suppressed only the response elicited by the corresponding immunogen. Fig. 5 shows that (N20 30)-HGG abolished the response to the corresponding immunogen. In contrast, the other type of tolerogen failed to diminish the response to the corresponding immunogen. Thus, tolerance induction to n-DNA was tolerogen specific. In 23 of 30 cases the suppression was 95% and in 7 cases 57-95%. Thus, of the 30 cases 7 were tolerized by (N20-30)-HGG before in vitro challenge with oligonucleotide (N20 30)-KLH and 18
were tolerized by (N1o-100)-HGG before challenge with (N1.o-10)-KLH. In four instances, different DNA fragments were used as either tolerogenic or immunogenic conjugates.
Thus, three were tolerized by (N0o-100)-HGG before challenge with (N20.30)-KLH and one was tolerized by (N20.30)-HGG before challenge with (N0o-100)-KLH. Fig. 6 antibody elicited by (NIO-1oo) linked to KLH can be suppressed by (NjO1OO)-HGG ( Fig. 7) .
Finally, in some experiments we observed that PBL preincubated with human gammaglobulin together with oligonucleotide (control mixture) resulted in either a decrease or increase ofthe immune response elicited by the immunogen. We examined the role of either the carrier (HGG) or the hapten (oligonucleotides) in producing this phenomenon. We found that in 15% of the cases HGG could decrease the response of the immunogen, although the suppression was less profound than the tolerogen (Fig. 8 ). In contrast, in 6 of 30 cases preincubation with oligonucleotide alone appears to prime the antigeninduced immune response (shown in Fig. 5, Exp. 1 and Fig. 7 ).
Discussion
The development of an antigen-specific immunotherapy for SLE has been hampered not by the ability to induce tolerance to nucleic acid antigen (24, 26) , but by the inability to link fragments of DNA to protein carriers to accommodate the combining site of antinucleic acid antibodies made by the SLE patients (22, 27) . We have previously shown that oligonucleotide linked to KLH is immunogenic (23) . In this paper we have shown that similar DNA fragments linked to human gammaglobulin are tolerogenic, since either spontaneous or antigeninduced anti-d-DNA or anti-n-DNA can be specifically diminished by preincubation of cultured lymphoid cells with DNA fragments linked to HGG. These results obtained in IgM anti-d-DNA and anti-n-DNA Ab humans in vitro extend earlier studies done in experimental animals in vivo in which tolerance was induced to small nucleic acid antigens such as nucleosides or nucleotides (24, 28, 29) . Spontaneous production of antibody to DNA was reduced by preincubation with tolerogen in 60% of the cases. In contrast, antigen-induced antibody production was abrogated in all cultures tested but one. Why is this so? First, the amount of spontaneous antibody formed is relatively small and the nature of the endogenous antigen, if any, that stimulates its production is still ill-defined. Second, since both B and T cells' (30) autoreactivity might account for the small amount of antibody spontaneously formed, polyclonal activation might be more resistant to tolerance induction than that induced by exogenous nucleic acid antigen challenge in vitro in which the specificities of tolerogen and immunogen are similar.
Clearly the diminution of spontaneous antibody to either d-DNA or n-DNA was tolerogen specific. Why the immune response in certain patients' PBL was suppressed by both types of tolerogens whereas others were tolerized by either tolerogen is unclear, since the large DNA fragments (NO-100) contain the small fragments (NIO30). It is known that SLE patients make antibody that recognizes either small or large DNA fragments (27, 31) . It is conceivable that after covalent linkage of oligonucleotides ofdifferent sizes to the carrier molecule (HGG) the degree of conjugation and/or the spatial presentation of tolerogens might influence their binding to the receptor on lymphoid cells. Furthermore, there is variability in the specificity of natural anti-DNA antibody production not only among patients' lymphoid cells but also at different times for the same patients' lymphoid cells. Therefore, it was important to test the same tolerogens in the same patients' PBL in the course of the disease. The results ofsuch a longitudinal study showed that in 12 patients' PBL examined several times, the same tolerogens gave consistent results. Similar results were obtained for diminution of anti-DNA antibody elicited by antigen challenge in vitro. On the other hand, there is a group producing spontaneous antibody in which the results are either variable or inconsistent. Because in SLE the auto-antibodies to DNA are polyspecific (6) the variability of the results in some patients' PBL may also reflect the complexity of this issue. It should be emphasized that both IgM and IgG antibodies to d-DNA or n-DNA formed either spontaneously or after an antigen-induced response in vitro were suppressed. Because high avidity IgG reacting with n-DNA and fixing complement not only causes tissue damage (32) , but also correlates with disease activity (14, 19, 33) , the observation that IgG antibody to n-DNA can be reduced may have therapeutic value.
Other workers have proposed different therapeutic strategies to suppress anti-DNA antibodies in PBL of SLE patients in vitro. For example, either nucleic acid antigens or antiidiotypic antibodies to DNA have been covalently linked to immunotoxic drugs in an attempt to delete the clone of B cells producing anti-DNA antibody (34, 35) . In murine models other investigators have also shown that nucleoside linked to dGL or DNA fragments linked to poly-d-lysine together with cyclophosphamide can suppress anti-DNA antibodies resulting in clinical improvement of murine lupus (36, 37) . In this study, we have not examined the mechanism of tolerance in vitro, but in other human models involving haptens linked to HGG we have shown that not only B cells but also T cells are involved (38, 39) . Clearly the tolerogenicity of the conjugate is determined by the carrier molecule HGG. Oligonucleotides have to be covalently linked to the carrier for the conjugate to be tolerogenic, since the mixture of oligonucleotide and HGG is ineffective. The observation that in some instances preincubation with HGG alone can diminish anti-DNA antibody formation is not surprising in view of the finding that HGG suppresses polyclonal activation in vitro (40) and intravenous administration of HGG may interfere with T-B cell cooperation (41) . Thus, even if HGG may nonspecifically downregulate the immune response, this further supports its choice as a tolerogenic carrier molecule.
The spontaneous production of anti-DNA antibody by cultured lymphoid cells from people with SLE provides an in vitro model to test the tolerogenicity of DNA fragments of various sizes linked to HGG. Further experiments are needed to determine whether the specificity of the antibody produced by lymphoid cells in vitro corresponds to that produced in the serum in vivo. This question bears on the issue of whether "generic" or "custom-made" tolerogens have to be constructed for the treatment of the disease.
Whether administration of oligonucleotides linked to HGG will influence the production not only of anti-DNA antibodies but also of other antibodies cross-reactive to this antigen is unknown. The specific suppression of anti-DNA antibodies by the induction ofimmunologic tolerance to DNA might not only allow examination of the role played by immune complexes containing nucleic acid but also that of immune complexes irrelevant to DNA in the pathogenesis of the disease. In conclusion, these data obtained in humans in vitro together with preliminary data obtained in (NZB X NZW) Fl mice (42) suggest that the principles of tolerance can be applied to specifically modulate undesirable autoimmune responses.
